首页> 外文期刊>Hepato-gastroenterology. >Lateral lymph node dissection for lower rectal cancer.
【24h】

Lateral lymph node dissection for lower rectal cancer.

机译:外侧淋巴结清扫术可治疗下直肠癌。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: This study was conducted to evaluate the effects of lateral lymph node dissection (LLD) on overall survival, disease-free survival, and local recurrence for the patients with lower rectal cancer. METHODOLOGY: From 1990 through 2000, 169 consecutive patients with T2 (TNM classification) or more advanced, extended lower rectal cancer (located below the peritoneal reflection) underwent curative resection at Kanagawa Cancer Center were reviewed. One hundred and forty-three patients who underwent LLD and the 26 patients who did not were entered in this study. RESULTS: Cox's multivariate regression analysis showed T stage (TMN classification), N stage (TNM classification), and LLD were found to be significantly related to the rates of both cumulative survival and disease-free survival. That mean LLD was identified as a significant prognostic factor. But disease-free survival did not differ significantly between the patients who underwent LLD and those who did not undergo LLD in stage I, II, or III disease (p = 0.3681, p = 0.1815, and p = 0.0896, respectively). The local recurrence rate was similar in patients who received LLD (17.5 percent) and in those who did not receive LLD (23.1 percent; p = 0.498). But 7 patients with lateral lymph node metastasis (33.3 percent) remained disease free. And these patients had local lateral lymph node metastasis and benefited from LLD. CONCLUSIONS: LLD can substantially improve outcomes in selected patients at high risk for lateral lymph node metastasis. A randomized controlled clinical study is necessary to clarify the role of LLD in the treatment of rectal cancer.
机译:背景/目的:这项研究旨在评估下直肠癌患者的淋巴结清扫术(LLD)对总体生存,无病生存和局部复发的影响。方法:从1990年到2000年,在神奈川县癌症中心对169例连续的T2(TNM分类)或更晚期,下直肠直肠癌(位于腹膜反射下方)的患者进行了根治性切除术。接受LLD的143例患者和未接受LLD的26例患者进入本研究。结果:Cox的多元回归分析显示T期(TMN分类),N期(TNM分类)和LLD与累积生存率和无病生存率显着相关。这意味着LLD被确定为重要的预后因素。但是,在I,II或III期疾病中接受LLD的患者和未接受LLD的患者之间,无病生存率没​​有显着差异(分别为p = 0.3681,p = 0.1815和p = 0.0896)。接受LLD的患者(17.5%)和未接受LLD的患者(23.1%; p = 0.498)的局部复发率相似。但是有7例有侧淋巴结转移的患者(占33.3%)仍然没有疾病。这些患者有局部外侧淋巴结转移,并从LLD中受益。结论:LLD可以显着改善部分高侧淋巴结转移风险的患者的预后。为了阐明LLD在直肠癌治疗中的作用,必须进行随机对照临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号